A Randomized, Bilateral Comparison, Vehicle-Controlled, Safety and Tolerability Study of Topical PAT-001 for the Treatment of Congenital Ichthyosis

Trial Profile

A Randomized, Bilateral Comparison, Vehicle-Controlled, Safety and Tolerability Study of Topical PAT-001 for the Treatment of Congenital Ichthyosis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Apr 2017

At a glance

  • Drugs Isotretinoin (Primary)
  • Indications Congenital ichthyosiform erythroderma
  • Focus Adverse reactions; Proof of concept
  • Sponsors Patagonia Pharmaceuticals
  • Most Recent Events

    • 17 Jan 2017 Status changed from not yet recruiting to recruiting.
    • 07 Nov 2016 According to an Almirall media release, this trial will initiate in Q1 2017.
    • 18 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top